Skip to main content
OpenTrials

Clinical trial condition

Refractory Follicular Lymphoma

Explore clinical trials studying Refractory Follicular Lymphoma. Study availability and eligibility vary by location and protocol.

35 public trials 6 recruiting studies
Refine in advanced search Browse all conditions

Refractory Follicular Lymphoma trial results

Active, Not Recruiting

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

NCT04224493

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Southern Cancer Center Mobile, Alabama, United States
  • Arizona Oncology Associates - Tuscon-Rusadill Road Tucson, Arizona, United States
  • TOI - Clinical Research Cerritos, California, United States
  • UCSF Fresno Clovis, California, United States
View all 204 locations
View Trial Details
Active, Not Recruiting

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

NCT03269669

Conditions
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, +12 more
Locations
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Anchorage Oncology Centre Anchorage, Alaska, United States
View all 429 locations
View Trial Details
Active, Not Recruiting

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

NCT03598998

Conditions
Anaplastic Large Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Hemic and Lymphatic Diseases, +35 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • University of Nebraska Medical Center Omaha, Nebraska, United States
View Trial Details
Active, Not Recruiting

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

NCT05627245

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +24 more
Locations
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Yale University New Haven, Connecticut, United States
  • University of Kansas Clinical Research Center Fairway, Kansas, United States
  • University of Kansas Cancer Center Kansas City, Kansas, United States
View Trial Details
Active, Not Recruiting

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

NCT01955499

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +21 more
Locations
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada
View Trial Details
Active, Not Recruiting

Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

NCT01849263

Conditions
Grade 3a Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
  • Metro Minnesota Community Oncology Research Consortium Saint Louis Park, Minnesota, United States
View all 13 locations
View Trial Details

Related conditions